ating Skin Nectar with TriHex+™ technology, a new formulation with our proprietary Octapeptide45 which helps reinforce skin structure, restore skin barrier and support long-term skin longevity.

Therapeutic Dermatology

Therapeutic Dermatology net sales reached 385 million USD for the first quarter of 2026, up 71.3% year-on-year at constant currency.

Growth was driven by Nemluvio’s continued strong launch trajectories in both reporting geographies, compleented by anticipated moderate growth from the mature Therapeutic Dermatology portfolio in International markets during the period. This more than offset the decline of the mature portfolio in the U.S.

Nemluvio net sales for the quarter were 185 million USD. The vast majority of sales came from the U.S., with a greater contribution from atopic dermatitis than prurigo nodularis.

In the U.S., Nemluvio paid new patient starts (NBRx) from the beginning of February to mid-March 2026
=*=*=*=*=*=
当前为第8/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页